Ceribell, a prominent medical technology company specializing in advanced neurodiagnostic solutions, has shared new findings from a multi-center retrospective study.

The study, published in Neurocritical Care, compares outcomes using the Ceribell system with traditional electroencephalography (EEG) and highlights several advantages of Ceribell.

Key findings include:

• 4.1 days shorter median ICU stay with Ceribell compared to conventional EEG.
• 18 percentage point decrease in the proportion of patients discharged with poor functional disability scores when assessed with Ceribell.
• 19 hours faster median time to EEG acquisition with Ceribell (5.9 hours) compared to conventional EEG (25.3 hours).

The study, a sub-analysis of 283 patient records from the SAFER-EEG trial, demonstrates the Ceribell system's effectiveness in improving patient outcomes by reducing ICU stays and accelerating EEG acquisition, while also highlighting its clinical and economic benefits in managing non-convulsive seizures and status epilepticus.

"The results underline the importance of early point-of-care EEG assessment. Ceribell's system not only improves patient care but also alleviates the burden on hospital resources."

Previously, the SAFER-EEG trial was conducted at four leading academic hospitals in the U.S., with results published in Neurology showing Ceribell’s comparable performance to traditional EEG in predicting seizure risk.

The Ceribell system, featuring highly portable hardware and an advanced AI-powered algorithm, is FDA 510(k) cleared for detecting suspected seizure activity and is used in ICUs and emergency rooms nationwide.

It has also received FDA Breakthrough Device Designations and, in 2023, a New Technology Add-on Payment (NTAP) from CMS for its Clarity™ algorithm.





Source: prnewswire.com

Report Abuse